This is a list of investigational bipolar disorder drugs, or drugs that are currently under development for clinical use for the treatment of bipolar disorder (manic depression) and related conditions but are not yet approved. Bipolar disorder and related conditions include bipolar I disorder, bipolar II disorder, cyclothymia, manic episodes, bipolar depression, and schizoaffective disorder (bipolar/manic and mixed types).
Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]".
This list was last comprehensively updated in May 2026. It is likely to become outdated with time.
Under development Preregistration Lurasidone (DSP-1349M; Latuda; SM-13496; SMP-13496) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders
Phase 3 ALM-008 – undefined mechanism of action (mood stabilizer) – bipolar disorders Azetukalner (1OP-2198; encukalner; VRX-621698; XEN-1101; XPF-008) – Kv7.2 and Kv7.3 potassium channel opener – bipolar depression Brenipatide (LY-3537031) – glucagon-like peptide-1 (GLP-1) receptor agonist and gastric inhibitory polypeptide (GIP) receptor agonist – bipolar disorders Brexpiprazole (Lu-AF41156; OPC-34712; OPDC-34712; Rexulti; Rxulti) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders Cycloserine/lurasidone (Cyclurad; D-cycloserine/lurasidone; lurasidone/cycloserine; NRX-101) – combination of cycloserine (ionotropic glutamate NMDA receptor glycine site partial agonist) and lurasidone (atypical antipsychotic/non-selective monoamine receptor modulator) – bipolar depression Lumateperone (Caplyta; ITI-007; ITI-722) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders Risperidone extended release (LYN-005) – atypical antipsychotic (non-selective monoamine receptor modulator) – schizoaffective disorder SEP-4199 (non-racemic amisulpride; aramisulpride/esamisulpride [85:15 ratio]) – dopamine D2 and D3 receptor antagonist and serotonin 5-HT2B and 5-HT7 receptor antagonist – bipolar depression Xanomeline/trospium chloride (BMS-986510; Cobenfy; KarXT; LY-246708/trospium chloride) – combination of xanomeline (non-selective muscarinic acetylcholine receptor agonist) and trospium chloride (peripherally selective non-selective muscarinic acetylcholine receptor antagonist) – bipolar disorders
Phase 2/3 Opakalim (BHV-7000; BPN-25203; KB-3061) – Kv7.2 and Kv7.3 potassium channel opener – bipolar disorders
Phase 2 Aldesleukin (ILT-101; interleukin-2; IL2; IL-2) – recombinant interleukin-2 (IL-2) replacement (interleukin-2 receptor agonist) – bipolar disorders Amdiglurax (ALTO-100; NSI-189) – unknown mechanism of action (hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator) – bipolar depression Brilaroxazine (RP-5000; RP-5063) – atypical antipsychotic (non-selective monoamine receptor modulator) – schizoaffective disorder Cenobamate (ONO-2017; Ontozry; senovamate; X-Copri; XCopri; YKP-3089) – voltage-gated sodium channel (VGSC) blocker and GABA release enhancer – bipolar disorders Desmethyl cariprazine prodrug (ABBV-932; RGH-932) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar depression, bipolar disorders Direclidine (HTL-0016878; NBI-1117568; NBI-568) – muscarinic acetylcholine M4 receptor agonist – bipolar I disorders Ebselen (DR-3305; ebselene; ebseleno; ebselenum; harmokisane; PZ-51; SPI-1005; SPI-3005) – various actions – bipolar disorders Elunetirom (ABX-002) – thyroid hormone receptor beta (TRβ) agonist – bipolar depression Icalcaprant (ABBV-1354; CVL-354) – κ-opioid receptor antagonist – bipolar depression JNJ-8942 – undefined mechanism of action – bipolar disorders JNJ-18038683 – serotonin 5-HT7 receptor antagonist – bipolar disorders JNJ-55308942 – purine P2X7 receptor antagonist – bipolar depression Lithium cocrystal (AL-001-Alzamend Neuro; lithium salicylate/L-proline cocrystal) – undefined mechanism of action (mood stabilizer) – bipolar disorders, bipolar I disorders N-Methylamisulpride (LB-102) – dopamine D2 and D3 receptor antagonist and serotonin 5-HT2B and 5-HT7 receptor antagonist – bipolar depression Navacaprant (BTRX-140; BTRX-335140; CYM-53093; NMRA-140; NMRA-335140) – κ-opioid receptor antagonist – bipolar depression OSU-6162 (PNU-9639; PNU-96391; PNU-96391A) – dopamine D2 receptor agonist, serotonin 5-HT2A receptor agonist, and so-called "dopamine stabilizer" – bipolar depression Psilocybin (COMP360; COMP-360) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and psychedelic hallucinogen – bipolar depression RAP-219 – AMPA receptor negative allosteric modulator – bipolar disorders Vortioxetine (Brintellix; LU-AA21004; LuAA 21004; Trintellix; Vortidif) – serotonin reuptake inhibitor, serotonin 5-HT1A and 5-HT1B receptor agonist, and serotonin 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist – bipolar depression Zuranolone (BIIB-125; S-812217; SAGE-217; SGE-797; Zurzuvae) – GABAA receptor positive allosteric modulator and neurosteroid – bipolar depression
Phase 1/2 Cariprazine (cariprazine depot) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders
Phase 1 Brilaroxazine (RP-5000; RP-5063) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders CB03-154 (CB-03; CB-003) – Kv7.2 and Kv7.3 potassium channel opener – bipolar disorders Scopolamine (DPI-385-CVS; DPI-386; DPI-386 Nasal Gel; DPI-386-SG; DPI-386-SS; DPI-387; DPI-521-CG; DPI-550-TBI; Inscop spray) – non-selective muscarinic acetylcholine receptor antagonist – bipolar depression
Clinical phase unknown LTX-001 – glutaminase inhibitor – bipolar disorders Quetiapine oral suspension – non-selective monoaminer eceptor modulator – bipolar disorders
Preclinical Estianeptine ((S)-tianeptine; TNX-4300) – peroxisome proliferator-activated receptor PPARβ/δ and PPARγ agonist
Research NORA-520 (NRT-023; brexanolone prodrug) – GABAA receptor positive allosteric modulator and neurosteroid (brexanolone prodrug) – bipolar disorders
Not under development No development reported AMG-581 – undefined mechanism of action – schizoaffective disorder Aripiprazole controlled release (ZY-102) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders Aripiprazole transdermal (AQS-1301) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders AZD-4451 – undefined mechanism of action – bipolar disorders Cariprazine (MP-214; Reagila; RGH-188; Symvenu; Vraylar; WID-RGC20) – atypical antipsychotic (non-selective monoamine receptor modulator) – schizoaffective disorder Elpetrigine (GW293273; JZP-4) – volgate-gated sodium channel blocker and calcium channel blocker – bipolar disorders Esketamine (Falkieri; PG061; S-ketamine) – ionotropic glutamate NMDA receptor antagonist – bipolar depression Paliperidone controlled-release (DLP-115) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders Research programme: long-acting neuropsychiatric therapeutics - Teva (NP-201; NP-202; NP-202-Teva; NP201-Teva; risperidone long-acting implant; ropinirole long-acting implant) – monoamine receptor modulators – bipolar disorders SKL-PSY (FZ-016; SKL-PSY/FZ-016) – serotonin 5-HT1A receptor agonist – bipolar disorders SPD-421 (DP-VPA) – voltage-gated sodium channel (VGSC) blocker, GABA transaminase (GABA-T) inhibitor, histone deacetylase inhibitor, other actions (valproic acid prodrug) – bipolar disorders SPN-802 – undefined mechanism of action – bipolar disorders Ziprasidone extended release (ziprasidone once-daily) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders
Suspended Uridine (RG-2417) – mitochondrial protein stimulant – bipolar disorders
Discontinued Armodafinil (CEP-10953; Nuvigil; R-modafinil) – atypical dopamine reuptake inhibitor (DRI) – bipolar depression Bifeprunox (DU-127090) – dopamine D2 and D3 receptor partial agonist and serotonin 5-HT1A receptor partial agonist – bipolar disorders BL-1020 (AN-168; CYP-1020; perphenazine GABA ester; perphenazine-4-aminobutyrate) – dopamine receptor antagonist and GABA receptor agonist – schizoaffective disorder Eslicarbazepine acetate (Aptiom; BIA 2-093; Exalief; SEP-0002093; SEP-2093; Stedesa; Zebinix) – voltage-gated sodium channel (VGSC) blocker (eslicarbazepine prodrug) – bipolar disorders Gabapentin (CI-945; Gabapen; GOE-3450; Neurontin) – gabapentinoid (α2δ voltage-dependent calcium channel blocker) – bipolar disorders Licarbazepine (GP-47779; LIC-477; licarbazapine) – voltage-gated sodium channel (VGSC) blocker Lisdexamfetamine (Elvanse; LDX; NRP-104; S-877489; SHP-489; SPD-489; Tyvense; Venvanse; Vyvanse) – norepinephrine–dopamine releasing agent (NDRA) – bipolar depression Lu AA39959 – ion channel modulator – bipolar depression, bipolar disorders Lu AF35700 – dopamine D1 receptor modulator, serotonin 5-HT2A receptor modulator, and serotonin 5-HT6 receptor modulator – schizoaffective disorder MK-8189 – phosphodiesterase PDE10A inhibitor – bipolar disorders MP-101 (LY-2979165) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist – bipolar disorders Oxcarbazepine (GP-47680; KIN-493; NPC-04; oxacarbazepine; TRI-476; Trileptal) – voltage-gated sodium channel (VGSC) blocker (licarbazepine prodrug) – bipolar disorders Oxcarbazepine extended-release – voltage-gated sodium channel (VGSC) blocker (licarbazepine prodrug) – bipolar disorders Paliperidone (9-hydroxyrisperidone; Invega; JNS-007ER; R0-76477; RO-76477) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders, manic episodes PF-04455242 (PF-4455242) – κ-opioid receptor antagonist – bipolar depression R-103 (ABS-103R; R-ABS-103; (R)-ABS-103) – "GABA receptor agonist" (valproic acid analogue) – bipolar disorders Radafaxine (GW-353162; bupropion metabolite) – norepinephrine–dopamine reuptake inhibitor (NDRI) – bipolar disorders Ralmitaront (NTX-2001; RG-7906; RO-6889450) – trace amine-associated receptor 1 (TAAR1) agonist – schizoaffective disorder Ramelteon (Rozerem; TAK-375; TAK-375SL) – melatonin MT1 and MT2 receptor agonist – bipolar depression, bipolar disorders Rapastinel (BV-102; GLYX-13; GLYX-13-peptide; GLYX-13-trifluoroacetate; TPPT-amide; TPPT-amide-trifluoroacetate) – ionotropic glutamate NMDA receptor glycine site partial agonist – bipolar depression Risperidone (risperidone LAI) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar disorders scyllo-Inositol (AZD-103; ELND-005; quercinitol; scyllitol; scyllocyclohexanehexol; scylloinositol) – undefined mechanism of action – bipolar disorders SEP-378608 – undefined mechanism of action – bipolar disorders SR-31742A (SR-31742) – sigma receptor modulator – manic episodes Topiramate (Epitomax; KW-6485; KW-6485P; MCN 4853; RWJ 17021; Topamax; Topimax; Topina) – various actions – bipolar disorders Vabicaserin (PF-05208769; PF-5208769; SCA-136) – serotonin 5-HT2C receptor agonist – bipolar disorders Vixotrigine (BIIB-074; CNV-1014802; GSK-1014802; raxatrigine) – Nav1.7 voltage-gated sodium channel (VGSC) blocker – bipolar disorders Vofopitant (GR-205171) – neurokinin NK1 receptor antagonist – bipolar disorders Ziprasidone (CP-88059-01; CP-88059-1; Geodon; ME-2112; RQ-00000003; Zeldox) – atypical antipsychotic (non-selective monoamine receptor modulator) – bipolar depression Zonisamide (AD-810; AD-810N; CI-912; Excegran; Kinaplase; PD-110843; Tremode; Trerief; Zonegran) – various actions – manic episodes
Clinically used drugs Approved drugs Atypical antipsychotics